[1] TORRE L A, SIEGEL R L, WARD E M,et al.Global cancer incidence and mortality rates and trends:An update[J].Cancer Epidemiol Biomarkers Prev, 2016,25(1):16-27. [2] FALCK A K, FERNÖ M, BENDAHL P O,et al.Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?[J].World J Surg, 2010, 34(7):1434-1441. [3] AITKEN S J, THOMAS J S, LANGDON S P,et al.Quantitative analysis of changes in er, pr and her2 expression in primary breast cancer and paired nodal metastases[J].Ann Oncol, 2010, 21(6):1254-1261. [4] KÜMLER I, BALSLEV E, KNOP AS,et al.Expression patterns of biomarkers in primary tumors and corresponding metastases in breast cancer[J].Appl Immunohistochem Mol Morphol, 2018, 26(1):13-19. [5] GEORGESCU R, BOROS M, MONCEA D,et al.Discordance rate in estrogen receptor, progesterone receptor, her2 status, and ki67 index between primary unifocal and multiple homogenous breast carcinomas and synchronous axillary lymph node metastases have an impact on therapeutic decision[J].Appl Immunohistom Mol Morphol, 2018, 26(8):533-538. [6] 徐雨杰, 王梦申, 王翀,等.Luminal A型乳腺癌原发灶与淋巴结转移灶表型标志物差异性研究[J].中华肿瘤防治杂志, 2018, 25(9):642-646. [7] 金梁斌, 姚自翔, 孔令泉,等.同期腋窝转移淋巴结受体检测在激素受体阴性乳腺癌中的临床意义[J].中国肿瘤临床, 2013, 40(15):911-913. [8] 刘琪, 左文述, 王新昭,等.乳腺癌原发灶和淋巴结转移灶激素受体及HER-2与Ki-67表达相关性分析[J].中华肿瘤防治杂志, 2013, 20(15):1153-1157. [9] 田枫, 张建国, 仲雷.乳腺浸润性导管癌病灶与腋窝转移淋巴结中ER和Her-2表达的关系[J].中国普通外科杂志, 2012, 21(11):1405-1409. [10] 房兆国, 范小超, 杨奔,等.乳腺癌原发灶与转移灶分子分型指标表达差异的研究[J].中华肿瘤防治杂志, 2017, 24(16):1175-1178. [11] DIECI M V, BARBIERI E, PIACENTINI F,et al.Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact:A single-institution analysis[J].Ann Oncol, 2013, 24(1):101-108. [12] FALCK A K, BENDAHL P O, CHEBIL G,et al.Biomarker expression and st gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up[J].Breast Cancer Res Treat, 2013, 140(1):93-104. [13] 杨文涛, 步宏.乳腺癌雌、孕激素受体免疫组织化学检测指南[J].中华病理学杂志, 2015,44(4):237-239. [14] 《乳腺癌HER2检测指南》编写组.乳腺癌HER2检测指南(2014版)[J].中华病理学杂志, 2014, 43(4):262-267. [15] COATES A S, WINER E P, GOLDHIRSCH A,et al.Tailoring therapies——improving the management of early breast cancer:St gallen international expert consensus on the primary therapy of early breast cancer 2015[J].Ann Oncol, 2015, 26(8):1533-1546. [16] FASCHING P A, HEUSINGER K, HAEBERLE L,et al.Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment[J].BMC Cancer, 2011, 11:486. [17] URRUTICOECHEA A, SMITH I E, DOWSETT M.Proliferation marker ki-67 in early breast cancer[J].J Clin Oncol, 2005, 23(28):7212-7220. [18] BOTTINI A, BERRUTI A, BERSIGA A,et al.Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer[J].Br J Cancer, 2001, 85(8):1106-1112. [19] KLEIN C A.Parallel progression of primary tumours and metastases[J].Nat Rev Cancer, 2009, 9(4):302-312. [20] LIU S L, CONG Y, WANG D,et al.Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts[J].Stem Cell Reports, 2014, 2(1):78-91. [21] NAROD S A, SOPIK V.Is invasion a necessary step for metastases in breast cancer?[J].Breast Cancer Res Treat, 2018, 169(1):9-23. [22] OSKARSSON T, BATLLE E, MASSAGUÉ J.Metastatic stem cells:Sources, niches, and vital pathways[J].Cell Stem Cell, 2014, 14(3):306-321. [23] MARUSYK A, TABASSUM D P, ALTROCK P M,et al.Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity[J].Nature, 2014, 514(7520):54-58. |